MOSCETTI, LUCA
MOSCETTI, LUCA
Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials. BMC Cancer
2020 Omarini, C; Piacentini, F; Sperduti, I; Barbolini, M; Isca, C; Toss, A; Cortesi, L; Barbieri, E; Dominici, M; Moscetti, L
DonnaRosa Project: Exploring Informal Communication Practices Among Breast Cancer Specialists
2025 Ferro, A.; Atzori, F.; Angiolini, C.; Bortolin, M.; Cortesi, L.; Fabi, A.; Fiorio, E.; Garrone, O.; Gianni, L.; Giordano, M.; Merlini, L.; Mion, M.; Moscetti, L.; Sartori, D.; Sarobba, M. G.; Spazzapan, S.; Lusardi, R.; Piras, E. M.
DonnaRosa Project: Exploring Informal Communication Practices Among Breast Cancer Specialists.
2025 Ferro, A; Atzori, F; Angiolini, C; Bortolin, M; Cortesi, L; Fabi, A; Fiorio, E; Garrone, O; Gianni, L; Giordano, M; Merlini, L; Mion, M; Moscetti, L; Sartori, D; Sarobba, Mg; Spazzapan, S; Lusardi, R; Piras, Em; Donnarosa, Group.
Male mammary myofibroblastoma: Two case reports and brief review of literature.
2020 Venturelli, M.; Toss, A.; Cortesi, L.; Gambini, A.; Andreotti, A.; Cascinu, S.; Tazzioli, G.; Moscetti, L
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
2023 Valenza, C.; Trapani, D.; Gandini, S.; Sposetti, C.; Boscolo Bielo, L.; Marra, A.; Giarratano, T.; Favero, D.; Cortesi, L.; Moscetti, L.; Pistelli, M.; Berardi, R.; Zambelli, A.; Lambertini, M.; Del Mastro, L.; Guarneri, V.; Vernieri, C.; Curigliano, G.
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
2022 Toss, A; Venturelli, M; Civallero, M; Piombino, C; Domati, F; Ficarra, G; Combi, F; Cabitza, E; Caggia, F; Barbieri, E; Barbolini, M; Moscetti, L; Omarini, C; Piacentini, F; Tazzioli, G; Dominici, M; Cortesi, L.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials. BMC Cancer | 1-gen-2020 | Omarini, C; Piacentini, F; Sperduti, I; Barbolini, M; Isca, C; Toss, A; Cortesi, L; Barbieri, E; Dominici, M; Moscetti, L | |
| DonnaRosa Project: Exploring Informal Communication Practices Among Breast Cancer Specialists | 1-gen-2025 | Ferro, A.; Atzori, F.; Angiolini, C.; Bortolin, M.; Cortesi, L.; Fabi, A.; Fiorio, E.; Garrone, O.; Gianni, L.; Giordano, M.; Merlini, L.; Mion, M.; Moscetti, L.; Sartori, D.; Sarobba, M. G.; Spazzapan, S.; Lusardi, R.; Piras, E. M. | |
| DonnaRosa Project: Exploring Informal Communication Practices Among Breast Cancer Specialists. | 1-gen-2025 | Ferro, A; Atzori, F; Angiolini, C; Bortolin, M; Cortesi, L; Fabi, A; Fiorio, E; Garrone, O; Gianni, L; Giordano, M; Merlini, L; Mion, M; Moscetti, L; Sartori, D; Sarobba, Mg; Spazzapan, S; Lusardi, R; Piras, Em; Donnarosa, Group. | |
| Male mammary myofibroblastoma: Two case reports and brief review of literature. | 1-gen-2020 | Venturelli, M.; Toss, A.; Cortesi, L.; Gambini, A.; Andreotti, A.; Cascinu, S.; Tazzioli, G.; Moscetti, L | |
| Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments | 1-gen-2023 | Valenza, C.; Trapani, D.; Gandini, S.; Sposetti, C.; Boscolo Bielo, L.; Marra, A.; Giarratano, T.; Favero, D.; Cortesi, L.; Moscetti, L.; Pistelli, M.; Berardi, R.; Zambelli, A.; Lambertini, M.; Del Mastro, L.; Guarneri, V.; Vernieri, C.; Curigliano, G. | |
| Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy | 1-gen-2022 | Toss, A; Venturelli, M; Civallero, M; Piombino, C; Domati, F; Ficarra, G; Combi, F; Cabitza, E; Caggia, F; Barbieri, E; Barbolini, M; Moscetti, L; Omarini, C; Piacentini, F; Tazzioli, G; Dominici, M; Cortesi, L. |